Document:

<PAGE>   1
                                                                   EXHIBIT 10.12

JOINT TECHNOLOGY AND COLLABORATION AGREEMENT entered into as of the 4th day of
February 2000.

BETWEEN:    ARIDIA CORP., a corporation incorporated under the laws of the
            Province of Nova Scotia (hereinafter the "Corporation")

AND:        INFECTIO DIAGNOSTIC (I.D.I.) INC., a corporation incorporated under
            the laws of the Province of Quebec (hereinafter "IDI")

AND:        CEPHEID, a corporation incorporated under the laws of the state of
            California (hereinafter "Cepheid")

WHEREAS, IDI has expertise and know-how relating to certain nucleic acid
sequences for identification and diagnosis of certain human infectious disease
parameters as hereinafter described;

WHEREAS, Cepheid has expertise and know-how relating to systems, subsystems and
non-reagent consumables (such as disposable reaction tube), for diagnosing human
disease parameters;

WHEREAS IDI and Cepheid have granted to the Corporation exclusive licenses in
the Field relating to their respective technology;

WHEREAS IDI, Cepheid and the Corporation have entered into a Shareholders
Agreement dated February 4, 2000; and

WHEREAS IDI and Cepheid desire to cooperate in the discovery and development of
innovative diagnostic systems based on the integration of their respective
technologies;

NOW THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth and other good and valuable consideration, the parties
hereby agree as follows:

<PAGE>   2
                                     - 2 -

                                    ARTICLE 1

                                   DEFINITIONS

As used in this agreement:

1.1   "AFFILIATE(s)" shall mean any corporation or other business entity
      controlled by or in common control of a party. "Control" as used herein
      means ownership directly or through one or more Affiliates, of fifty
      percent (50%) or more of the shares of stock entitled to vote for the
      election of directors, in the case of any corporation, or fifty percent
      (50%) or more of the equity interests in the case of any other type of
      legal entity, status as a general partner in any partnership, or any other
      arrangement whereby a party controls or has the right to control the board
      of directors or equivalent governing body of a corporation or other
      entity.

1.2   "CEPHEID" shall include all of the divisions, subsidiaries and Affiliates
      of Cepheid.

1.3   "CEPHEID INTELLECTUAL PROPERTY" shall mean all technology rights and
      patents rights (a) owned by Cepheid, existing as of the date hereof or
      developed subsequent to the date hereof and (b) relating to systems,
      subsystems and non reagent consumables for diagnosing human disease
      parameters including without limitations the patents and patents
      applications listed and described on Appendix A hereto. The Cepheid
      Intellectual Property shall also include any improvements, refinements,
      updates, discoveries or inventions related to Cepheid Intellectual
      Property and intellectual property developed by Cepheid in the course of
      the Collaboration Program.

1.4   "COLLABORATION PROGRAM" means any research program and associated
      activities contemplated by the parties during the term of this Agreement
      which program and activities shall, from time to time, be attached to this
      Agreement as Appendix B.

1.5   "COLLABORATIVE PRODUCTS" means any products which are discovered in whole
      or in part as a result of the Collaboration Program and made of Joint
      Technology.

1.6   "FIELD" shall mean the rapid diagnosis of human infectious diseases
      including but not limited to bacteria, fungi, antibiotic resistance and
      related disorders with systems integrating IDI Intellectual Property and
      Cepheid Intellectual Property.

1.7   "IDI" shall include all of the divisions, subsidiaries and Affiliates of
      IDI.

1.8   "IDI INTELLECTUAL PROPERTY" shall mean all technology rights and patent
      rights (a) owned by IDI, existing as of the date hereof or developed
      subsequent to the date hereof and (b) relating to nucleic acid sequences
      useful for the identification and/or diagnosis of human infectious disease
      parameters, including, without limitation, the patents and patent
      applications listed and described on Appendix C hereto. The IDI
      Intellectual Property shall also include any improvements, refinements,
      updates, discoveries or inventions related to IDI Intellectual Property
      and intellectual property developed by IDI in the course of the
      Collaboration Program.

1.9   "JOINT TECHNOLOGY" shall have the meaning ascribed to such term in section
      2.6.3. hereof.

1.10  "SHAREHOLDERS AGREEMENT" shall mean the Shareholders Agreement between
      IDI, Cepheid and the Corporation dated February 4, 2000, and any addenda
      and amendments of said agreement.

<PAGE>   3
                                     - 3 -

                                   ARTICLE 2

                              COLLABORATION PROGRAM

2.1   BASIC PROVISIONS

      The Collaboration Program shall aim at the development and
      commercialization of innovative diagnostic systems based on the
      integration of IDI Intellectual Property and Cepheid Intellectual
      Property.

2.2   COOPERATION

      Each party shall keep the board of directors of the Corporation fully
      informed about the status of the Collaboration Program, and scientists at
      IDI and Cepheid shall cooperate in the performance of the Collaboration
      Program and, subject to any confidentiality obligations to third parties,
      shall exchange information and materials as necessary to carry out the
      Collaboration Program.

2.3   EXPENSES

      IDI and Cepheid shall each bear all expenses of their participation in the
      Collaboration Program.

2.4   RESEARCH AND DEVELOPMENT

      The parties agree to jointly develop and prepare a written plan for any
      Collaboration Program which plan shall include without limitation:

      o     Product description and specifications

      o     Development Plan with specified tasks and milestones, including
            identified responsibilities of the respective parties

      o     Resourcing plan, budget and funding plan

      o     Regulatory plan

      o     Production plan

      o     Cost targets and analysis

2.5   DISCLOSURE OF INVENTION

      Each party shall promptly inform the other of all inventions that are
      conceived, made or developed in the course of carrying out the
      Collaboration Program by employees or consultants of either of them or
      their Affiliates alone or jointly with employees or consultants of the
      other party or its Affiliates. The following provisions shall apply to
      rights in the intellectual property developed by IDI or Cepheid, or both,
      during the course of carrying out the Collaboration Program.

2.6   OWNERSHIP

      The Corporation shall not own any intellectual property developed in the
      course of the Collaboration Program, which shall be owned as follows:

      2.6.1 IDI Technology

            IDI shall have sole and exclusive ownership of all rights, title and
            interest on a worldwide basis in and to any technology solely
            developed or created by employees or consultants of IDI or through
            the use of IDI Intellectual Property

<PAGE>   4
                                     - 4 -

            in the course of the Collaboration Program. This technology shall be
            included in IDI License.

      2.6.2 Cepheid Technology

            Cepheid shall have sole and exclusive ownership of all rights, title
            and interest on a worldwide basis in and to any technology solely
            developed or created by employees or consultants of Cepheid or
            through the use of Cepheid Intellectual Property in the course of
            the Collaboration Program. This technology shall be included in
            Cepheid License.

      2.6.3 Joint Technology

            IDI and Cepheid shall jointly own all technology jointly conceived,
            reduced to practice or developed jointly by employees or consultants
            of both IDI and Cepheid during the course of the Collaboration
            Program (the "Joint Technology") and shall jointly own all joint
            patent rights. The Joint Technology shall be included in IDI License
            and in Cepheid License. Technology shall be considered "jointly"
            conceived, reduced to practice, or developed if and only if it is
            the subject of a patent application showing authorship by at least
            one employee of each of Cepheid and IDI.

2.7   COMMERCIALIZATION RIGHTS

      The Corporation shall have the exclusive worldwide right to develop and
      commercialize Joint Technology and the Collaborative Products in the
      Field.

2.8   JOINT TECHNOLOGY OUTSIDE THE FIELD

      IDI and Cepheid shall not use the Joint Technology and the Collaborative
      Products outside the Field without the prior written consent of the other
      party.

2.9   FIRST NEGOTIATION RIGHT

      During the term of this Agreement, each party shall promptly disclose to
      the Corporation after the filing of a patent application any new
      intellectual property developed by such party (the "Inventor Party")
      outside the Collaboration Program which is subject to such patent
      application, but only to the extent that such property is of material use
      in the Field. The Corporation shall benefit of a first negotiation right
      over any third party to use, make, offer to sell and sell such new
      intellectual property in the Field. Upon receipt of a written notice from
      the Inventor Party, the Corporation shall have 30 days to notify the
      Inventor Party that it wishes to enter into negotiations. If the
      Corporation does not notify the Inventor Party within 30 day period that
      it wishes to enter into negotiations, then the Inventor Party shall be
      free to offer its new intellectual property to any third party on any
      terms. In the event that the Corporation exercises its right of first
      negotiation, the Inventor Party and the Corporation shall enter into good
      faith negotiations in order to conclude an agreement within 90 days from
      the expiration of the 30-day period. If the Corporation and the Inventor
      Party cannot reach an agreement despite good faith negotiations, then on
      or before the 90th day described in the preceding sentence, the
      Corporation shall deliver to the Inventor Party a detailed written offer
      of terms and conditions upon which it is willing, without additional
      negotiation, to acquire the right use, make, offer to sell, and sell the
      new intellectual property in the Field, and after the 90th day, the
      Inventor Party shall be free to offer the new intellectual property to any
      third party on terms and conditions not more favorable to the third party
      than the terms and

<PAGE>   5
                                     - 5 -

      conditions so offered by the Corporation. If the Corporation does not
      deliver such a written offer within 90-day period, then the Inventor Party
      may offer the new intellectual property to any third party on any terms.

                                    ARTICLE 3

                  PROVISIONS CONCERNING THE FILING, PROSECUTION

                        AND MAINTENANCE OF PATENT RIGHTS

3.1   FILING OF PATENTS

      In consultation with the board of directors of the Corporation, IDI will
      determine what patents will be filed on IDI Technology and Cepheid will
      determine what patents will be filed on Cepheid Technology developed in
      the course of the Collaboration Program. Each party will be responsible
      for the prosecution (including the defense of interferences and similar
      proceedings) of patent protection for its owned intellectual property,
      provided that the other party will have the opportunity to provide
      substantive review and comment on any such prosecution. Responsibility for
      prosecution of patent protection (including the defense of interferences
      and similar proceedings) on Joint Technology will be determined by the
      board of directors of the Corporation.

3.2   EXPENSES

      Each party shall bear all attorneys' fees, filing and maintenance fees and
      other out-of-pocket costs incurred by it pursuant to Section 3.1 to the
      extent they relate to its Intellectual Property except for Joint
      Technology in which case the Corporation shall bear all such costs.

3.3   RIGHT TO PROSECUTE ABANDONED RIGHTS

      If either party at any time elects (or causes the Corporation to elect)
      not to seek or continue to seek, use or maintain patent protection on any
      Joint Technology in any country, the other party shall have the exclusive
      right, at its expense, to file, procure, maintain and enforce in such
      countries patents on such intellectual property. Each party agrees to
      advise the other party of all decisions taken in a timely manner in order
      to allow a party to protect its rights under this Article 3. If a party
      elects not to file a patent application or application for a certificate
      of invention, not to maintain a patent or certificate of invention, or to
      abandon a pending patent application or application for a certificate of
      invention, it shall advise the other party of such election in a timely
      manner, and such other party shall have the right, at its own expense, of
      filing such application, maintaining such patent or certificate of
      invention or continuing to attempt to obtain protection on the subject
      matter disclosed in such pending application.

<PAGE>   6
                                     - 6 -

                                    ARTICLE 4

                       CONFIDENTIALITY AND NON-DISCLOSURE

      The parties agree that the Confidentiality provisions contained in the
      Shareholders Agreement apply to this Agreement, with the necessary changes
      having been made.

                                    ARTICLE 5

                              TERM AND TERMINATION

5.1   TERM

      This Agreement shall continue in full force and effect until the
      expiration of the 6 month period following receipt by IDI or Cepheid of a
      notice of winding up sent pursuant to Article 4 of the Shareholders
      Agreement.

5.2   SURVIVAL OF OBLIGATIONS

      Article 4 of this Agreement shall survive the termination of this
      Agreement.

                                    ARTICLE 6

                                    DISPUTES

6.1   NEGOTIATION AND MEDIATION

      If a dispute arises out of or relates to this Agreement or its breach (the
      "Matter"), the parties agree to resolve the Matter as follows:

      (a)   A party (the "Initiating Party") shall submit written notice of the
            Matter to the other parties and request negotiation.

      (b)   The parties shall attempt in good faith to resolve any Matter
            arising out of or relating to this Agreement promptly by negotiation
            between representatives which the parties may appoint, and

      (c)   If the Matter has not been resolved within 60 days of a party's
            request for negotiation, either party may request that the Matter be
            submitted to a sole mediator selected by the parties for mandatory
            mediation of not more than five days' duration;

6.2   ARBITRATION

      If the Matter has not been resolved by such mediation, either party may
      submit the Matter for binding arbitration, to a sole arbitrator in
      accordance with the Rules of Conciliation and Arbitration of the
      International Chamber of Commerce as in effect on the date hereof, (the
      "ICC Rules"), except where such ICC Rules conflict with the provisions of
      Article 6 in which event the provisions of this Article 6 shall prevail.

<PAGE>   7

                                     - 7 -

6.3   APPOINTMENT OF ARBITRATOR

      If the parties fail to agree on the appointment of the sole arbitrator
      within 20 days after one party has served the other party, a written
      notice to concur in the appointment of the single arbitrator nominated by
      the serving party, the sole arbitrator shall be appointed in accordance
      with the ICC Rules. If IDI is the Initiating Party, then the sole
      arbitrator shall be a member of the California Bar with at least 10 years
      of experience in corporate commercial or intellectual property law. If
      Cepheid is the Initiating Party, then the sole arbitrator shall be a
      member of the Quebec Bar with at least 10 years of experience in corporate
      commercial or intellectual property law. The arbitrator shall render any
      final award within 20 days following the completion of evidence and
      arguments on the Matter.

6.4   ADMISSIBILITY OF EVIDENCE IN OTHER PROCEEDINGS

      The parties shall not be entitled to rely on or introduce as evidence
      before any arbitral proceedings whether or not such proceedings relate to
      the Matter that is the subject of the negotiations:

      (a)   views expressed or suggestions made by another party in respect of a
            possible settlement of the Matter;

      (b)   admissions or proposals made by another party in the course of
            negotiations; or

      (c)   the fact that the other party had indicated his willingness to
            accept a proposal for settlement made by another party.

6.5   LOCATION

      The mediation and arbitration shall be held in Montreal, Quebec. The
      parties, their representatives, the mediator and the arbitrator shall hold
      the existence, content and results of any negotiation, mediation or
      arbitration in confidence unless disclosure is required by law or
      regulation, and in such case the parties shall take reasonable precautions
      to only disclose what is required by law or governmental regulation

6.6   AWARD

      Any award of the Arbitration shall be final and binding on the parties and
      shall be enforceable in any court having jurisdiction over the party from
      whom enforcement is requested.

                                    ARTICLE 7

                                     NOTICES

      Any notice, request, instruction or other document to be given hereunder
      shall be deemed validly given if in writing, and delivered personally,
      sent by overnight courier, or sent by certified mail, postage prepaid,
      return receipt requested (in which event it shall be deemed received on
      the third business day following mailing), as follows:
<PAGE>   8
                                     - 8 -

        If to IDI:
        ---------

        Infectio Diagnostic (I.D.I.), Inc.
        2050 Rene Levesque Blvd. West
        Ste-Foy, Quebec, Canada G1V 2K8
        Attn:  Dr. Pierre Coulombe
        Facsimile: (418) 681-5254

        if to Cepheid:
        -------------

        Cepheid
        1190 Borregas Avenue
        Sunnyvale, CA, USA, 94089-1302
        Attn:  Thomas L. Gutshall
        Facsimile: (408) 541-4192

        and if to the Corporation:
        -------------------------

        Aridia Corp.
        2050 Rene Levesque Blvd. West
        Ste-Foy, Quebec, Canada G1V 2K8
        Attn:  Dr. Pierre Coulombe
        Facsimile: (418) 681-5254

        With copy to Thomas L. Gutshall
        Facsimile: (408) 541-4192

        Alternatively, notices and other communications may be sent by facsimile
        transmission with a confirmation copy sent by one of the forms of
        delivery set forth above. Except as provided above, all notices and
        other communications shall be deemed delivered on the date of actual
        receipt.

                                    ARTICLE 8

                                  MISCELLANEOUS

8.1   ENTIRE AGREEMENT

      This Agreement along with the Shareholders Agreement and the exclusive
      licenses between IDI and the Corporation and Cepheid and the Corporation
      constitutes the entire understanding between the parties with respect to
      the subject matter hereof and supersedes and replaces all prior
      agreements, understandings, writings and discussions between the parties
      relating to said subject matter. Only a written instrument executed by the
      parties may amend this Agreement.

8.2   WAIVER

      The failure of either party at any time or times to require performance of
      any provision hereof shall in no manner affect its rights at a later time
      to enforce the same. No waiver by either party of any condition or term in
      any one or more

<PAGE>   9
                                     - 9 -

      instances shall be construed as a further or continuing waiver of such
      condition or term or any other condition or term.

8.3   SUCCESSORS AND ASSIGNS

      This Agreement shall be binding upon and inure to the benefit of and be
      enforceable by the parties hereto and their respective successors and
      assigns and neither IDI, Cepheid or the Corporation shall assign this
      Agreement without the prior written consent of the other parties, which
      cannot be unreasonably withheld.

8.4   FORCE MAJEURE

      Any delays in or failure of performance by either party under this
      Agreement shall not be considered a breach of this Agreement if and to the
      extent caused by occurrences beyond the reasonable control of the party
      affected, including but not limited to acts of God; acts, regulations, or
      laws of any government; strikes or other considered acts of workers;
      fires; floods; explosions; riots; wars; rebellion; and sabotage; and any
      time for performance hereunder shall be extended by the actual time of
      delay caused by such occurrence.

8.5   SEVERABILITY

      If any provision(s) of this Agreement are or become invalid, or ruled
      illegal by any court of competent jurisdiction, or are deemed
      unenforceable under then current applicable law from time to time in
      effect during the term hereof, it is the intention of the parties that the
      remainder of this Agreement shall not be affected thereby. It is further
      the intention of the parties that in lieu of each such provision which is
      invalid, illegal, or unenforceable, there be substituted or added as part
      of this Agreement, a provision which shall be as similar as possible in
      economic and business objectives as intended by the parties to such
      invalid, illegal, or unenforceable provision, but which shall be valid,
      legal, and enforceable, and shall be mutually agreed by the parties.

8.6   HEADINGS

      The headings contained herein are for reference purposes only and shall
      not in any way affect the meaning of this Agreement.

8.7   COUNTERPARTS

      This Agreement may be executed in any number of counterparts, each of
      which shall be an original, but all of which together shall constitute one
      instrument.

8.8   NO AGENCY

      Nothing contained in this Agreement shall be deemed to create a
      partnership between the Corporation, IDI and Cepheid. Neither party shall
      be liable for the act of the others unless each other parties expressly
      authorizes such act in writing.

8.9   GOVERNING LAW

      As to matters affecting Cepheid Intellectual Property, this Agreement
      shall be governed by and construed in accordance with the laws of the
      State of California, without regard to the application of principles of
      conflicts of laws thereof. As to other matters, this Agreement shall be
      governed by and construed in accordance with the laws of the Province of
      Quebec, without regard to the application of principles of conflicts of
      laws thereof.

<PAGE>   10
                                     - 10 -

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

INFECTIO DIAGNOSTIC (I.D.I.) INC            ARIDIA CORP.

Per:  /s/ PIERRE COULOMBE                   Per: /s/ PIERRE COULOMBE
    ------------------------------              ------------------------------
      Dr. Pierre Coulombe                        Dr. Pierre Coulombe

                                            Per:  /s/ THOMAS L. GUTSHALL
                                                ------------------------------
                                                   Thomas L. Gutshall

CEPHEID

Per:  /s/ THOMAS L. GUTSHALL
    ------------------------------
        Thomas L. Gutshall

<PAGE>   11
                                   APPENDIX A

                          CEPHEID INTELLECTUAL PROPERTY

<PAGE>   12
                                   APPENDIX A

               TO THE JOINT TECHNOLOGY AND COLLABORATION AGREEMENT
     BETWEEN AND ARIDIA CORP., INFECTIO DIAGNOSTIC (I.D.I.) INC. AND CEPHEID

                              COLLABORATION PROGRAM

I.    Reaction vessel for heat-exchanging chemical processes.

<TABLE>
<CAPTION>
                                PATENT
         COUNTRY                NUMBER            ISSUES
         -------                ------            ------
        <S>                  <C>               <C>
        UNITED STATES         US 5,958,349     Sept. 28, 1999

</TABLE>

<PAGE>   13

                                   APPENDIX B

                              COLLABORATION PROGRAM

<PAGE>   14
                                   APPENDIX B

               TO THE JOINT TECHNOLOGY AND COLLABORATION AGREEMENT
     BETWEEN AND ARIDIA CORP., INFECTIO DIAGNOSTIC (I.D.I.) INC. AND CEPHEID

                              COLLABORATION PROGRAM

<PAGE>   15

                                   APPENDIX C

                            IDI INTELLECTUAL PROPERTY

<PAGE>   16
                                   APPENDIX C

               TO THE JOINT TECHNOLOGY AND COLLABORATION AGREEMENT
     BETWEEN AND ARIDIA CORP., INFECTIO DIAGNOSTIC (I.D.I.) INC. AND CEPHEID

                       IDI PATENT RIGHTS AND APPLICATIONS

I.    Specific and universal probes and amplification primers to rapidly detect
      and identify common bacterial pathogens and antibiotic resistance genes
      from clinical specimens for routine diagnosis in microbiology
      laboratories.

<TABLE>
<CAPTION>
                        APPLICATION        FILING
COUNTRY                   NUMBER            DATE              STATUS

<S>                    <C>             <C>                  <C>
AUSTRALIA              34 681/95       Sept 12, 1995         292494

BRAZIL                 08/304732       Sept 12, 1995         Pending

CANADA                 1529278         April 2, 1998         Pending

CHINA                  CN1161060A      Oct 1, 1997           Pending

UNITED STATES          US526840        Nov 4, 1996           6,001,564

EUROPE              95 931 109.3-2116                        Pending

INDIA                  2153CAL97                             Pending

JAPAN                  504973/98       May 19, 1998          Pending

MEXICO                 97/01847        June 18, 1997         Pending

NORWAY                 971111          Sept. 1, 1998         Pending

NEW ZEALAND            JP207909        August 12, 1998       292494

SINGAPORE              9701090-4       Sept. 12, 1995        9701090-4
</TABLE>

<PAGE>   17

II.   Species-specific, genus-specific and universal DNA probes and
      amplification primers to rapidly detect and identify common bacterial and
      fungal pathogens and associated antibiotic resistance genes from clinical
      specimens for diagnosis in microbiology laboratories.

<TABLE>
<CAPTION>
                        APPLICATION        FILING
COUNTRY                   NUMBER            DATE              STATUS

<S>                    <C>             <C>                  <C>

ARGENTINA              P970105357       Nov. 14, 1997         Pending

AUSTRALIA              48598/97         Nov. 14, 1997         Pending

BRAZIL                 PI 9713494-5     Nov. 14, 1997         Pending

CANADA                 5044400          July 22, 1999         Pending

CHINA                  97180194.0       Nov. 4, 1997          Pending

UNITED STATES          WO98/20157       Nov. 4, 1997          Pending

EUROPE                 97911094.7 - 2116                      Pending

INDIA                  2153CAL97        Nov. 13, 1997         Pending

JAPAN                                   May 6, 1999           Pending

MEXICO                 99-4119          May 3, 1999           Pending

NORWAY                 19991976         April 26, 1999        Pending

NEW ZEALAND            335548           June 4, 1999          Pending

SINGAPORE              9901915-0        Nov. 4, 1997          Pending
</TABLE>

<PAGE>   18

III.  Highly conserved genes and their use to generate species-specific,
      genus-specific, family-specific, group-specific and universal nucleic acid
      probes and amplification primers to rapidly detect and identify bacterial,
      fungal and parasitical pathogens from clinical specimens for diagnosis.

<TABLE>
<CAPTION>
                        APPLICATION        FILING
COUNTRY                   NUMBER            DATE              STATUS

<S>                      <C>             <C>                  <C>
CANADA                CAN 2,283,458     Sept. 28, 1999        Pending
</TABLE>

<PAGE>   19

IV.   Specific and universal probes to rapidly detect and identify common
      bacteria form urinary or any other biological samples in the routine
      microbiology laboratory.

<TABLE>
<CAPTION>
                        APPLICATION        FILING
COUNTRY                   NUMBER            DATE              STATUS

<S>                      <C>             <C>                  <C>
UNITED STATES         85-586-9001-2     Sept. 12, 1994      08/304,732

UNITED STATES S.N.    850586.90012      Sept. 11, 1995      08/526,840
</TABLE>

<PAGE>   20

V.    Species-specific and universal DNA probes and amplification primers to
      rapidly detect and identify common bacterial pathogens and associated
      antibiotic resistance genes from clinical specimens for routine diagnosis
      in microbiology laboratories.

<TABLE>
<CAPTION>
                        APPLICATION        FILING
COUNTRY                   NUMBER            DATE              STATUS

<S>                      <C>             <C>                  <C>
UNITED STATES          US 743,637        Nov. 4, 1996        5,994,066
</TABLE><PAGE>   1
                                                                   EXHIBIT 10.13

SHAREHOLDERS AGREEMENT entered into as of the 4th day of February, 2000.

BETWEEN  INFECTIO DIAGNOSTIC (I.D.I.) INC., a corporation incorporated under the
         laws of the Province of Quebec ("IDI")

AND      CEPHEID, a corporation incorporated under the laws of the state of
         California ("Cepheid")

AND      ARIDIA CORP., a corporation incorporated under the laws of the Province
         of Nova Scotia ("Corporation")

WHEREAS the Corporation is a company incorporated under the Nova Scotia
Companies Act by Certificate of Incorporation dated the 4th day of February,
2000, and is qualified as a Nova Scotia Unlimited Liability Company;

WHEREAS the share capital of the Corporation consists of a limited number of
1,000,000 common shares of which 200 common shares have been issued and are
presently outstanding and registered as follows:

<TABLE>
<CAPTION>

               NAME                                       COMMON SHARES
               ----                                       -------------
              <S>                                         <C>
               IDI                                             100

               Cepheid                                         100
</TABLE>

WHEREAS IDI and the Corporation have entered concurrently with the execution of
this Agreement into a License and Supply Agreement;

WHEREAS Cepheid and the Corporation have entered concurrently with the execution
of this Agreement into a License and Supply Agreement;

WHEREAS the parties wish to enter into this Agreement in order to record their
mutual understanding as to the manner in which the affairs of the Corporation
shall be conducted and to provide for their respective rights and obligations;

NOW THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth and other good and valuable consideration, the parties
hereby agree as follows:

<PAGE>   2

                                      -2-

                                    ARTICLE 1

                                 INTERPRETATION

1.1   DEFINITIONS

      The capitalized words and expressions used in this Agreement or in its
      Schedules, or in any deed or agreement supplemental or ancillary hereto,
      unless there be something in the subject or the context inconsistent
      therewith, shall have the meanings respectively:

      "AFFILIATE" shall mean any corporation or other business entity controlled
      by or in common Control of a party. "Control" as used herein means
      ownership directly or through one or more Affiliates, of fifty percent
      (50%) or more of the shares of the share capital entitled to vote for the
      election of directors, in the case of any corporation, or fifty percent
      (50%) or more of the equity interests in the case of any other type of
      legal entity, status as a general partner in any partnership, or any other
      arrangement whereby a party controls or has the right to control the board
      of directors or equivalent governing body of a corporation other entity.

      "AUDITORS" means the auditors of the Corporation appointed pursuant to the
      provisions of Section 3.6 hereof;

      "BOARD" means the board of directors of the Corporation;

      "BUSINESS DAY" means any day excluding Saturday, Sunday and any other day
      which in the city of Quebec, Canada or in the State of California is a
      legal holiday or a day on which financial institutions are authorized by
      law or by local proclamation to close;

      "CEPHEID DIRECTOR" means the Directors appointed pursuant to the
      provisions of subsection 3.2.1 hereof;

      "CEPHEID LICENSE" means the License and Supply Agreement between Cepheid
      and the Corporation dated February 4, 2000;

      "COLLABORATION AGREEMENT" means the Joint Technology and Collaboration
      Agreement between IDI, Cepheid and the Corporation dated February 4, 2000;

      "CONTROL" means ownership directly or through one or more Affiliates, of
      fifty percent (50%) or more of the shares of the share capital entitled to
      vote for the election of directors, in the case of any corporation, or
      fifty percent (50%) or more of the equity interests in the case of any
      other type of legal entity, status as a general partner in any
      partnership, or any other arrangement whereby a party controls or has the
      right to control the board of directors or equivalent governing body of a
      corporation or other entity;

      "DIRECTOR" or "DIRECTORS" means a member or the members of the Board;

      "EFFECTIVE DATE" means February 4, 2000;

      "FISCAL YEAR" shall have the meaning ascribed to such term in Section
      3.2.8 hereof;

<PAGE>   3

                                      -3-

      "HEADS OF AGREEMENT" means the Heads of Agreement between IDI and Cepheid
      dated August 5, 1999;

      "IDI DIRECTORS" means the directors appointed pursuant to the provisions
      of subsection 3.2.1 hereof;

      "IDI LICENSE" means the License and Supply Agreement between IDI and the
      Corporation dated February 4, 2000;

      "LIEN" means any interest in property or the income or profits therefrom
      securing an obligation owed to, or a claim by, a Person other than the
      owner (which for the purposes hereof shall include a possessor under a
      title retention agreement and a lessee under a lease hereinbelow
      described) of such property, whether such interest is based on civil law,
      common law, statute or contract, and including but not limited to any
      security interest, hypothec, mortgage, pledge, lien, claim, charge,
      cession, transfer, assignment, encumbrance, title retention agreement,
      lessor's interest under a lease which would be capitalized on a balance
      sheet of the owner of such property or analogous interest in, of or on any
      property or the income or profits therefrom of a Person;

      "PERSON OR PERSON" means any individual, company, corporation,
      partnership, firm, trust, sole proprietorship, government or entity
      howsoever designated or constituted;

      "SHARES" means shares in the share capital of the Corporation which have
      been issued and are outstanding at any time and from time to time;

      "SHAREHOLDERS" means the parties to this Agreement and each Person to whom
      any Shares may at any time and from time to time be issued, each
      transferee of Shares and the respective representatives, administrators,
      successors and assigns of each of the above-mentioned Persons;

      "THIS AGREEMENT", the "AGREEMENT", "HERETO", "HEREIN", "HEREBY",
      "HEREUNDER" and similar expressions mean or refer to this Shareholders
      Agreement as amended from time to time and any indenture, agreement or
      instrument supplemental or ancillary hereto or in implementation hereof,
      and the expressions "SECTION", "SUBSECTION" and "CLAUSE" followed by a
      number or letter mean and refer to the specified section, subsection or
      paragraph of this Agreement;

1.2   GENERAL INTERPRETATION

      Unless there be something in the subject or the context inconsistent
      therewith, words importing the singular only shall include the plural and
      vice versa, and words importing the masculine gender shall include the
      feminine gender, and vice versa, and all references to dollars shall mean
      Canadian dollars, the legal currency of Canada.

1.3   DIVISION INTO ARTICLES

      The division of this Agreement into articles, sections, subsections,
      paragraphs and subparagraphs and the insertion of titles are only meant to
      be reference and do not affect the meaning or the interpretation of this
      Agreement.

<PAGE>   4
                                      -4-

1.4   ACCOUNTING PRINCIPLES

      All calculations required to be made under the terms hereof and all
      financial statements shall be prepared in accordance with the generally
      accepted accounting principles applied in Canada on a consistent basis.

1.5   GOVERNING LAW

      This Agreement and the interpretation and enforcement thereof shall be
      governed by the laws of the Province of Quebec without regard to any
      conflicts of law principles and the federal laws of Canada applicable
      therein.

                                    ARTICLE 2

                           PURPOSE OF THE CORPORATION

2.1   PURPOSE OF THE CORPORATION

      The Corporation was created by IDI and Cepheid in order to engage
      primarily in the business of developing, producing and exploiting a series
      of innovative human diagnostic systems and products for rapid
      identification of pathogens responsible for human infectious diseases
      based on the integration of proprietary technologies of IDI and Cepheid.

                                    ARTICLE 3

                 ORGANIZATION AND MANAGEMENT OF THE CORPORATION

3.1   SHAREHOLDERS

      The Shareholders shall each vote all Shares from time to time held by each
      of them and otherwise exercise their rights as Shareholders and, to the
      extent permitted by applicable law, cause their respective nominees to the
      Board to act, so that at all times the general provisions of the by-laws
      and the conditions, restrictions, limitations and prohibitions on the
      business and corporate affairs of the Corporation set forth in this
      Agreement shall apply and be given full effect.

3.2   GENERAL BY-LAWS

      The Articles of Association of the Corporation shall provide for the
      following continuing provisions with respect to the organization and
      management of the Corporation:

      3.2.1 Number of Directors

            The Board shall consist of 6 Directors who shall be nominated and
            elected as follows:

            (a)   IDI shall be entitled to nominate and have elected 3 Directors
                  (the "IDI Directors"); and

<PAGE>   5
                                      -5-

            (b)   Cepheid shall be entitled to nominate and have elected 3
                  Directors (the "Cepheid Directors").

      3.2.2 Meetings of Directors

            Subject to the provisions of applicable law, the following
            procedures shall apply to meetings of Directors of the Corporation

            (a)   Regular meetings of the Board shall be held at least 4 times
                  per year, with a minimum period of 2 months and a maximum
                  period of 3 months between each meetings. Other meetings of
                  the Board shall be held at such time as may be requested by
                  any Director;

            (b)   A meeting of the Board may be called by any Director, provided
                  at least 3 Business Days prior written notice is sent to all
                  Directors. A Director may waive notice of a meeting of the
                  Board, and the attendance of a Director at a meeting shall
                  constitute a waiver of notice of the meeting (except where a
                  Director attends a meeting for the express purpose of
                  objecting to the transaction of business on the grounds that
                  the meeting is not properly called) Meetings may be held by
                  conference telephone call;

            (c)   A quorum of a meeting of the Board shall consist of 6
                  Directors;

      3.2.3 Unanimous Vote to Govern - Directors' Meetings

            All decisions of the Board shall be decided by the unanimous vote of
            all the Directors present in person.

      3.2.4 Ostensible Authority

            No officer or Director of the Corporation may enter into any
            contract for or on behalf of the Corporation which involves the
            payment or obligation by the Corporation of an aggregate amount in
            excess of $10,000, or has an aggregate term (including any renewal
            term or extended term) of more than 12 months, without the prior
            approval of the Board, evidenced by resolution of the said Board.
            The Shareholders shall take the appropriate measures to ensure that
            the officers and the Directors of the Corporation comply with this
            provision.

      3.2.5 Business transaction

            Until any vacancy on the Board is filled in accordance with Section
            3.4, the Directors shall not transact any business.

      3.2.6 Meetings of Shareholders

            A meeting of the Shareholders may be called by the Board, provided
            at least 10 Business Days prior written notice is sent to the
            Shareholders. A Shareholder may waive notice of a meeting of the
            Shareholders, and the attendance of a Shareholder at a meeting shall
            constitute a waiver of notice of the meeting (except where a
            Shareholder attends a meeting for the express purpose of objecting
            to the transaction of business on the grounds that the meeting is
            not properly called).

<PAGE>   6
                                      -6-

      3.2.7 Quorum of Meetings of Shareholders

            A quorum of a meeting of the Shareholders of the Corporation shall
            consist of all the Shareholders.

      3.2.8 Fiscal Year

            The fiscal year end of the Corporation shall be December 31 of each
            year.

      3.2.9 Amendment or repeal

            The Directors shall not make, amend or repeal any by-laws except if
            the Shareholders have unanimously voted for such by-law, amendment
            or repeal.

3.3   FIRST DIRECTORS

      The first IDI Directors shall be:

      Dr. Michel. G. Bergeron
      Dr. Pierre Coulombe
      Mr. Jacques Millette

      and the first Cepheid Directors shall be:

      Mr. Thomas L. Gutshall
      Mr. Cris McReynolds
      Dr. Kurt Petersen.

3.4   ELECTION, REMOVAL AND VACANCIES

      The Shareholders shall each vote the Shares from time to time held by each
      of them and otherwise exercise their rights to ensure that Directors are
      elected or appointed and maintained in office and vacancies on the Board
      are filled in conformity with the provisions of Section 3.2.1 hereof. Each
      of the Shareholders shall have the right to remove any Director previously
      proposed by it and, if requested to do so, the other Shareholder shall
      vote the Shares from time to time held by it for the removal of any such
      Director and in favor of any substitute proposed by the Shareholder
      requesting such removal.

3.5   OFFICERS

      The officers of the Corporation shall be:

      Dr. Pierre Coulombe                 President
      Mr. Thomas L. Gutshall              Chairman of the Board
      Mr. Francois Duchesneau             Secretary

      and such other officers as may be appointed from time to time by the
      Board. The officers of the Corporation shall be appointed annually.

3.6   AUDITOR

      PricewaterhouseCoopers LLP shall be the auditors of the Corporation. Each
      of the Shareholders may from time to time request the auditors to perform,
      at the cost of such Shareholder, accounting and auditing tasks in addition
      to those functions that the auditors would ordinarily perform.

<PAGE>   7

                                      -7-

3.7   ACCOUNTING

      The books of account and all other financial records of the Corporation
      shall be kept and maintained at all times at the principal business office
      of the Corporation in the Province of Quebec. The Shareholders, or their
      agents, representatives and employees, shall be entitled to have access to
      and inspect all such books and records during normal business hours. They
      shall also be entitled, at their own expense, to obtain copies of such
      books and records.

3.8   CORPORATION

      The Corporation agrees to carry out and be bound by the provisions of this
      Agreement as it applies to it to the fullest extent permitted by law.

3.9   UNITED STATES TAX STATUS

      The Corporation shall make any election requested by Cepheid regarding its
      status as a corporation or a partnership for United Sates tax purposes.

                                    ARTICLE 4

               RESTRICTIONS ON TRANSFER OF SHARES AND EXIT RIGHTS

4.1   GENERAL RESTRICTION ON TRANSFER

      No Shareholder may sell, transfer, alienate or otherwise dispose or divest
      itself of or create, incur, assume or suffer to exist any Lien on all or
      part of its Shares except in conformity with the provisions of this
      Article 4.

4.2   EXIT RIGHTS

      Each of the Shareholders (the "Petitioner") shall be entitled at any time
      after 18 months after the Effective Date to send a written notice to the
      other Shareholder and the Corporation requesting the winding up of the
      Corporation (the "Winding up Notice"). The Shareholders and the
      Corporation agree in advance that the winding up of the Corporation shall
      be effective 6 months after the receipt by the other Shareholder and the
      Corporation of the Winding up Notice.

4.3   EFFECT OF WINDING UP NOTICE

      Upon the receipt by the other Shareholder and the Corporation of a Winding
      up Notice, the other Shareholder and the Corporation shall have 30 days to
      notify in writing the Petitioner that they will collaborate to wind up the
      Corporation, in which case the winding up of the Corporation shall be
      effective 180 days after receipt of the Winding up Notice.

      4.3.1 Rules of voluntary winding up

            If the other Shareholder and the Corporation have agreed to
            collaborate to voluntary wind up the Corporation, the following
            rules shall apply:

            (a)   The Shareholders and the Corporation shall take all acts
                  necessary or useful to voluntary wind up the Corporation
                  within 180 days after the receipt of the Winding up Notice.

<PAGE>   8
                                      -8-

            (b)   The Corporation shall carry on business until 180 days after
                  receipt by a Shareholder and the Corporation of the Winding up
                  Notice. At the expiration of the 180 day period, the
                  Corporation shall cease to carry on business except to the
                  extent necessary for the finalization of the winding up of the
                  Corporation.

            (c)   During the 180 day period, the Corporation shall take all
                  appropriate measures to complete the sale of any Collaborative
                  Products and Products to third party pursuant to any then
                  outstanding agreements and the Shareholders agree to negotiate
                  in good faith to restructure any agreements to which the
                  Corporation was a party for the distribution and sale of the
                  Collaborative Products and Products or to put in place new
                  agreements to enable continued supply of the Collaborative
                  Products and Products sold by the Corporation to a third party
                  distributor after the Corporation has ceased to carry on
                  business.

      4.3.2 Expiration of the 180 day period

            At the expiration of the 180 day period:

            (a)   The Corporation shall cease to use IDI Intellectual Property
                  and Cepheid Intellectual Property.

            (b)   IDI shall have a fully paid-up, worldwide license under
                  Cepheid Intellectual Property to use, offer to sell and sell
                  products based upon Cepheid Intellectual Property in the
                  Field, which license shall be in conformity with the terms and
                  conditions of the Cepheid License.

            (c)   Cepheid shall have a fully paid-up worldwide license under IDI
                  Intellectual Property to use, offer to sell and sell products
                  based upon IDI Intellectual Property in the Field, which
                  license shall be in conformity with the terms and conditions
                  of the IDI License.

            (d)   Cepheid and IDI will negotiate in good faith for supply
                  agreements pursuant to which IDI would supply Cepheid with IDI
                  Products and Cepheid would supply IDI with Cepheid Products.

4.4   APPLICATION TO THE COURT

      If the other Shareholder and/or the Corporation have (i) failed within the
      30 day period set forth in Subsection 4.3.1 to notify the Petitioner that
      they will collaborate in the winding up of the Corporation, (ii) notified
      the Petitioner that they will not collaborate in the winding up of the
      Corporation, or (iii) notified the Petitioner that they will collaborate
      in the winding up of the Corporation but failed to do so at the
      satisfaction of the Petitioner, then the parties hereby irrevocably agree
      that upon application to the Trial Division of the Supreme Court of the
      Province of Nova Scotia, the Court shall render an order for winding up of
      the Corporation according to the rules set forth in Section 4.3 and in
      accordance with the Companies Winding Up Act (Nova Scotia).

<PAGE>   9
                                      -9-

4.5   SALE, MERGER AND ACQUISITION OF CONTROL

      In addition to the Exit Rights provided in Section 4.2 and following, a
      Shareholder may send at any time a Winding up Notice to the other
      Shareholder and the Corporation in the event of (i) the transfer or sale
      of all or substantially all of the asset of the other Shareholder, (ii)
      the merger of the other Shareholder with a third party; (except for
      mergers solely for the purpose of changing the legal domicile of a party)
      or (iii) the acquisition by a third party of the Control of the other
      Shareholder and the provisions of Sections 4.3 and 4.4 shall apply to any
      such Winding up Notice.

4.6   NO REGISTRATION

      Without prejudice to any other recourses that may be exercised in such a
      case, any Lien created, incurred, assumed or suffered to exist, directly
      or indirectly, in contravention of this Agreement, and any sale, transfer,
      assignment, alienation or other disposition of the Shares effected in
      contravention hereof (whether directly or indirectly) shall, for all
      intents and purposes, with regard to the other Shareholder and the
      Corporation, be null, void and without effect and shall not be registered
      in the books of the Corporation, any such registration being without
      effect

4.7   LEGEND OF SHARE CERTIFICATES

      All of the share certificates of the share capital of the Corporation
      shall bear the following conspicuous inscription:

            "Ownership, conveyance and encumbrance of the Shares represented by
            this certificate are subject to the terms of the Shareholders
            Agreement dated February 4, 2000."

4.8   DEFINITIONS

      All terms used in this Article 4 which are defined in the Collaboration
      Agreement, the IDI License and the Cepheid License are used herein with
      the meanings defined therein.

                                    ARTICLE 5

                                 CONFIDENTIALITY

5.1   UNDERTAKING

      The Shareholders hereby acknowledge and agree that they have been and will
      be given access to or otherwise come into contact with information
      relating to the businesses, operations, properties, assets, liabilities
      and financial conditions of the Corporation, of business partners of the
      Corporation, of a Shareholder or of a shareholder of a Shareholder,
      including without limitation, information relating to business plans and
      ideas, trade secrets, invention, processes, methods, know-how, policies,
      materials, results of operations, financial and statistical information,
      personnel data and customer, supplier and price lists, which are
      considered by

<PAGE>   10

                                      -10-

      the Corporation, the business partner of the Corporation, the Shareholder
      or the shareholder of a Shareholder, as the case may be, to be valuable,
      secret and confidential (hereinafter referred to as the "Confidential
      Information"). Each of the Shareholders hereby agrees that it will not,
      for any purpose, at any time that it is a Shareholder and for a period of
      5 years following the date upon which it ceases to be a Shareholder, allow
      one of its shareholders, directors, officers, employees or agents during
      the same period, to make public, disclose, divulge, furnish, transfer,
      sell, release or otherwise make available to any Person, firm,
      association, partnership, syndicate, company or corporation any of the
      Confidential Information or otherwise use any of the Confidential
      Information or allow any of the Confidential Information to be used for
      any purpose other than, during the period during which a party hereto
      remains a Shareholder, for the purposes of advancing the interests of and
      for the entire benefit of the Corporation.

      The foregoing non-use and non-disclosure obligations assumed by each party
      shall not apply to information which (i) was in its possession prior to
      the date of execution of the Heads of Agreement, (ii) is disclosed to it
      by a third party not bound by obligations of confidentiality to the party
      disclosing the information or to any third party, or (iii) is generally
      available to the public.

5.2   SURVIVAL

      The undertaking set forth in Section 5.1 shall survive and continue in
      full force the winding up of the Corporation.

                                    ARTICLE 6

                                  MISCELLANEOUS

6.1   SUCCESSORS AND ASSIGNS

      The provisions of this Agreement shall, except as otherwise provided
      herein, enure to the benefit of and be binding upon the parties hereto and
      their respective representatives, successors assigns and each and every
      Person so bound shall make, execute and deliver all documents necessary to
      carry out this Agreement.

6.2   NOTICES

      Any notice or other communication to be given hereunder may be effectively
      given to a party by delivering the same at the addresses hereinafter set
      forth or by sending the same by prepaid registered mail, prepaid courier
      or telecopy or e-mail (in the case of telecopy or e-mail with confirmation
      of receipt) to such party at such addresses. Any notice so mailed shall be
      deemed to have been received on the third Business Day following the
      mailing thereof and if given by delivery or telecopy the same shall be
      deemed to have been received upon delivery or upon transmission. The
      mailing and telecopy address of the parties for the purpose hereof shall
      be:

<PAGE>   11
                                      -11-

      (a)   as to the Corporation:
            ---------------------

               Aridia Corp.
               2050 Rene-Levesque Blvd. West
               4th floor
               Sainte-Foy, Quebec
               G1V 2K8
               Attention: Dr. Pierre Coulombe
               Facsimile: (418) 681-5254

               And copy to: Thomas L. Gutshall
               Facsimile: (408) 541-4192

      (b)   as to IDI:
            ---------

               Infectio Diagnostic (I.D.I.) Inc.
               2050 Rene-Levesque Blvd. West
               4th floor
               Sainte-Foy, Quebec
               G1V 2K8
               Attention: Dr. Pierre Coulombe
               Facsimile: (418) 681-5254

      (c)   as to Cepheid:
            -------------

               Cepheid
               1190 Borregas Avenue
               Sunnyvale, CA, 94089-1302
               Attention: Thomas L. Gutshall
               Facsimile: (408) 541-4192

6.3   WAIVERS

      The rights and remedies of the Shareholders under this Agreement shall be
      cumulative and not exclusive of any rights or remedies which they would
      otherwise have and no failure or delay by any Shareholder in exercising
      any right shall operate as a waiver thereof, not shall any single or
      partial exercise of any power or right preclude its other or further
      exercise or the exercise of any other power or right.

6.4   AMENDMENTS

      This Agreement may be amended only by written agreement duly executed by
      all the parties hereto.

6.5   TIME OF ESSENCE

      Time shall be of the essence of this Agreement.

<PAGE>   12
                                      -12-

6.6   COUNTERPARTS

      This Agreement may be executed in one or more counterparts each of which
      when so executed shall be deemed to be an original and such counterparts
      together shall constitute but one of the same instrument.

6.7   SEVERABILITY

      Any provision of this Agreement which is prohibited or unenforceable in
      any jurisdiction shall, as to such jurisdiction, be ineffective to the
      extent of such prohibition or unenforceability without invalidating the
      remaining provisions hereof in that jurisdiction or affecting the validity
      or unenforceability of such provision in any other jurisdiction.

6.8   REPLACEMENT OF HEADS OF AGREEMENT

      The present Agreement replaces and supersedes the Heads of Agreement and
      all other verbal or oral agreements, understandings and undertakings
      between the parties hereto relating to the transaction contemplated
      herein.

6.9   LANGUAGE

      The parties hereto have expressly required that this Agreement and all
      deeds, documents and notice relating thereto be drafted in the English
      Language. Les parties aux presentes ont expressement exige que la presente
      convention et tous les autres contrats, documents ou avis qui y sont
      afferents soient rediges en langue anglaise.

6.10  CONFLICT

      In the event of any conflict between the provisions of this Agreement on
      the one hand and the Memorandum and Articles of Association on the other,
      the provisions of this Agreement shall govern. Each Shareholder agrees to
      vote or cause to be voted the Shares owned by him as necessary so as to
      cause the Memorandum and Articles of Association to be amended to resolve
      any such conflict in favor of the provisions of this Agreement.

      IN WITNESS WHEREOF this Agreement has been executed on the date
hereinabove first set forth.

INFECTIO DIAGNOSTIC (I.D.I.) INC.            ARIDIA CORP.

Per: /s/ DR. PIERRE COULOMBE                 Per: /s/ DR. PIERRE COULOMBE
    ----------------------------                 -----------------------------
      Dr. Pierre Coulombe                          Dr. Pierre Coulombe

CEPHEID
                                             Per: /s/ THOMAS L. GUTSHALL
                                                 -----------------------------
                                                     Thomas L. Gutshall
Per:   /s/ THOMAS L. GUTSHALL
    ------------------------------
        Thomas L. Gutshall

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]